135.42
0.34%
0.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$134.96
Aprire:
$134.98
Volume 24 ore:
1.96M
Relative Volume:
2.10
Capitalizzazione di mercato:
$13.71B
Reddito:
$2.24B
Utile/perdita netta:
$385.90M
Rapporto P/E:
72.81
EPS:
1.86
Flusso di cassa netto:
$440.10M
1 W Prestazione:
+6.88%
1M Prestazione:
+9.84%
6M Prestazione:
+1.01%
1 anno Prestazione:
+12.56%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
135.42 | 13.71B | 2.24B | 385.90M | 440.10M | 3.73 |
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-10-10 | Ripresa | Raymond James | Outperform |
2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2023-12-13 | Ripresa | Citigroup | Neutral |
2023-12-12 | Iniziato | Deutsche Bank | Buy |
2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
2023-08-21 | Reiterato | Mizuho | Neutral |
2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
2022-10-11 | Iniziato | UBS | Buy |
2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
2022-06-06 | Ripresa | Jefferies | Buy |
2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-09-23 | Ripresa | Needham | Hold |
2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
2021-05-18 | Ripresa | Goldman | Neutral |
2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
2021-02-02 | Iniziato | Raymond James | Outperform |
2020-09-30 | Iniziato | The Benchmark Company | Hold |
2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
2020-06-29 | Downgrade | Goldman | Buy → Neutral |
2020-06-09 | Iniziato | Wedbush | Outperform |
2020-03-06 | Iniziato | Citigroup | Buy |
2020-02-27 | Iniziato | Barclays | Equal Weight |
2020-02-24 | Iniziato | William Blair | Outperform |
2020-02-06 | Iniziato | Mizuho | Neutral |
2020-02-05 | Reiterato | H.C. Wainwright | Buy |
2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
2019-07-16 | Iniziato | Oppenheimer | Outperform |
2019-06-05 | Iniziato | Guggenheim | Neutral |
2019-05-21 | Iniziato | Credit Suisse | Outperform |
2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
2019-04-12 | Iniziato | Evercore ISI | Outperform |
2019-02-06 | Reiterato | BofA/Merrill | Buy |
2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
2018-12-13 | Iniziato | Goldman | Buy |
2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga
Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter
Needham & Company LLC Reaffirms "Hold" Rating for Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat
Neurocrine launches CRENESSITY for adrenal hyperplasia in US By Investing.com - Investing.com South Africa
Neurocrine Bioscience’s CRENESSITY Becomes Commercially Available In The U.S. - Contract Pharma
Neurocrine launches CRENESSITY for adrenal hyperplasia in US - Investing.com
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PR Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 1,091 Shares - MarketBeat
Neurocrine Biosciences chief regulatory officer sells $147,285 in shares - Investing.com
Neurocrine Biosciences chief regulatory officer sells $147,285 in shares By Investing.com - Investing.com UK
Neurocrine Biosciences' SWOT analysis: stock outlook mixed amid pipeline setbacks - Investing.com Canada
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth - Seeking Alpha
Tidal Investments LLC Acquires 5,197 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
HighTower Advisors LLC Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine wins FDA OK for first-in-class CAH drug - The Pharma Letter
Franklin Resources Inc. Sells 144,114 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
FDA Tracker: Neurocrine, Checkpoint Score FDA Approvals - BioSpace
Neurocrine’s First New CAH Treatment in 70 Years Gets FDA Approval - geneonline
Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder - MedCity News
Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years - Citeline News & Insights
Blockbuster bound? Neurocrine’s hyperplasia drug approved - BioWorld Online
Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug - Yahoo! Voices
Neurocrine Biosciences (NASDAQ:NBIX) Trading 5% HigherHere's What Happened - MarketBeat
Novo builds up manufacturing; Pepgen Duchenne trial put on hold - BioPharma Dive
Neurocrine Biosciences rises on FDA nod for CAH drug By Investing.com - Investing.com Australia
Neurocrine Biosciences rises on FDA nod for CAH drug - Investing.com
Neurocrine Biosciences (NASDAQ:NBIX) Receives "Outperform" Rating from William Blair - MarketBeat
FDA clears Neurocrine drug for rare adrenal disorder - pharmaphorum
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Benzinga
Neurocrine Biosciences (NASDAQ:NBIX) Given Outperform Rating at Wedbush - MarketBeat
Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Goldman Sachs lifts Neurocrine Bio shares target, buy rating on FDA approval - Investing.com Canada
Launch complexities temper expectations for Neurocrine Bio stock, says BMO Capital - Investing.com Australia
Geode Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
(NBIX) Technical Data - Stock Traders Daily
Public Employees Retirement System of Ohio Sells 6,046 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Barclays PLC - MarketBeat
Neurocrine wins FDA approval for CAH therapy - MSN
Neurocrine wins FDA approval for CAH therapy (NBIX:NASDAQ) - Seeking Alpha
Neurocrine Biosciences to Participate at Investor Conferences in December - The Eastern Progress Online
US FDA approves Neurocrine Biosciences’ genetic disorder drug - 1470 & 100.3 WMBD
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia - Longview News-Journal
US FDA approves Neurocrine Biosciences' genetic disorder drug - Reuters.com
Virtu Financial LLC Invests $1.99 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Tri Ri Asset Management Corp Acquires New Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
4,191 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by EP Wealth Advisors LLC - MarketBeat
aTyr Pharma Strengthens Board with Neurocrine CCO Eric Benevich, Bolsters Commercial Leadership - StockTitan
Neurocrine Biosciences' SWOT analysis: stock faces mixed pipeline results, regulatory challenges - Investing.com
Tri Ri Asset Management Corp Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Vestcor Inc Trims Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Delaet Ingrid | Chief Regulatory Officer |
Dec 17 '24 |
Sale |
135.00 |
1,091 |
147,285 |
2,507 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):